RainDance Technologies and Ambry Genetics collaborate to
develop ADME genetic screening panel
19 March 2011
RainDance Technologies, Inc. and Ambry Genetics have announced
a new collaboration for the development of a drug absorption,
distribution, metabolism, and excretion (ADME) genetic screening panel
for use on next-generation sequencing (NGS) systems.
ADME analysis is a critical part of the drug discovery and
development process, providing important data on how a compound
reaches the blood stream and whether distribution, metabolism and
excretion are affected by factors such as age, sex, ethnicity or
In recent years, the biotechnology and pharmaceutical industries
have been performing ADME screening earlier in an effort to reduce
the significant costs associated with failed drug trials and
hospitalizations due to adverse events. Scientific studies indicate
that more effective indicators of atypical drug metabolism and
molecular pharmacology could help reduce hospitalizations associated
with adverse drug events by 50% or more.
Current genotyping tools for ADME research lack the genetic
sensitivity, genomic coverage, and resolution necessary to detect
many of the important mutations associated with adverse drug events.
The new ADME panel developed by RainDance and Ambry will give the
capacity to perform sequence analysis of entire coding regions
associated with more than 220 key drug metabolism-linked genes
including transporters, receptors, regulators and all
pharmacodynamics and pharmacogenetic genes, as well as all US
FDA-identified pharmacogenomic biomarker genes.
The new panel, provided as part of the Ambry ADME sequencing
service, will leverage RainDance’s proprietary primer design methods
and microdroplet-based RDT 1000 platform, which provides the highly
accurate, consistent, and reproducible results required in ADME
research and for most FDA drug applications.